Bosentan Tablets.

Bosentan is a dual endothelin receptor antagonist, which is mainly clinically suitable for adult patients with pulmonary arterial hypertension (PAH) (WHO Group 1) and PAH of WHO functional grade II-IV (WHO Group 1).
Pulmonary arterial hypertension (PAH) (WHO Group 1): Improve pulmonary vascular resistance (PVR) in pediatric patients with idiopathic or congenital PAH aged ≥3 years, which is expected to improve exercise capacity.
Adult patients with PAH of WHO functional grade II-IV (WHO Group 1): To improve exercise capacity and reduce clinical deterioration. Mainly patients with idiopathic or hereditary etiology of WHO functional grade II-IV PAH (60%), PAH associated with pulmonary arterial hypertension (21%) and PAH associated with congenital heart disease with left-to-right shunt (18%).